.jetcityimage/iStock Editorial via Getty Images Morgan Stanley has actually picked Eli Lilly (NYSE: LLY) as its own best biopharma selection for 2025 and measured yet another 9 names in the area as overweight. The investment banking company claimed in a details that it remains to feel “diabesity is actually readied to end up being.